Hemophilia A Therapeutic Pipeline Analysis, 2022 | Latest FDA and EMA Approvals, Clinical Trials, Emerging Therapies | BioMarin (ROCTAVIAN), Novo Nordisk (Concizumab), Alnylam/Sanofi (Fitusiran)

 Breaking News
  • No posts were found

Hemophilia A Therapeutic Pipeline Analysis, 2022 | Latest FDA and EMA Approvals, Clinical Trials, Emerging Therapies | BioMarin (ROCTAVIAN), Novo Nordisk (Concizumab), Alnylam/Sanofi (Fitusiran)

September 30
19:30 2022
Hemophilia A Therapeutic Pipeline Analysis, 2022 | Latest FDA and EMA Approvals, Clinical Trials, Emerging Therapies | BioMarin (ROCTAVIAN), Novo Nordisk (Concizumab), Alnylam/Sanofi (Fitusiran)
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 35+ key pharma and biotech companies are working on 45+ pipeline drugs in the Hemophilia A therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Hemophilia A Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Hemophilia A Market. 

The Hemophilia A Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Hemophilia A Pipeline Analysis

Hemophilia A Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Hemophilia A and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia A Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Hemophilia A market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Latest Developments in the Hemophilia A Therapeutics Market

On Aug. 24, 2022, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that the European Commission (EC) had granted conditional marketing authorization (CMA) to ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy. BioMarin’s ROCTAVIAN™ is approved for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients without a history of Factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5).

DelveInsight’s Report covers around 45+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Hemophilia A Therapeutic Segment:

https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight

Hemophilia A Therapeutics Landscape

The treatment goal for Hemophilia is to replace the missing blood clotting factor so that the blood can clot properly. Medication to treat hemophilia A is a concentrated FVIII product. Several new treatments for hemophilia A are under development, from gene therapy to new non-factor replacement therapies. 

There are approx. 35+ key companies are developing therapies for Hemophilia A. Novo Nordisk has its Hemophilia A drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Hemophilia A therapeutics market include:

• Alnylam Pharmaceuticals

• Sanofi Genzyme

• Novo Nordisk

• Catalyst Biosciences

• Dimension Therapeutics

• Chia Tai Tianqing Pharmaceutical Group

• Staidson Beijing BioPharmaceuticals

• Kymab

• Poseida Therapeutics

• Intellia Therapeutics

• Regeneron Pharmaceuticals

• Hoffmann-La Roche

• Spark Therapeutics

• BioMarin

• Centessa Pharmaceuticals

• Expression Therapeutics

• Chugai Pharmaceutical

• Pfizer

• Biomarin Pharmaceutical

• Sangamo therapeutics

And many others

Hemophilia A Drugs Covered in the report include:

• Fitusiran: Alnylam Pharmaceuticals/Sanofi Genzyme

• Concizumab (NN7415): Novo Nordisk

• Marstacimab (PF-06741086)

• Marzeptacog alfa

• Valoctocogene Roxaparvovec

• BIVV001

• SPK-8011

• SB-525

And many more 

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Hemophilia A Current Treatment Patterns

4. Hemophilia A – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hemophilia A Late Stage Products (Phase-III)

7. Hemophilia A Mid-Stage Products (Phase-II)

8. Hemophilia A Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hemophilia A Discontinued Products

13. Hemophilia A Product Profiles

14. Key Companies in the Hemophilia A Market

15. Key Products in the Hemophilia A Therapeutics Segment

16. Dormant and Discontinued Products

17. Hemophilia A Unmet Needs

18. Hemophilia A Future Perspectives

19. Hemophilia A Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/hemophilia-a-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight 

Klinefelter Syndrome Market

“Klinefelter Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Klinefelter Syndrome Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories